These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38671056)

  • 21. 2011 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
    [No Abstract]   [Full Text] [Related]  

  • 22. Many FDA-approved cancer drugs might lack clinical benefit.
    Das M
    Lancet Oncol; 2018 Feb; 19(2):e82. PubMed ID: 29276024
    [No Abstract]   [Full Text] [Related]  

  • 23. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
    Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
    JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA new drug approvals in Q1 2021.
    Urquhart L
    Nat Rev Drug Discov; 2021 May; 20(5):334. PubMed ID: 33854219
    [No Abstract]   [Full Text] [Related]  

  • 25. Should the FDA be the doctor of last resort?
    DeVita VT
    Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
    [No Abstract]   [Full Text] [Related]  

  • 26. StatBite. FDA-required postmarketing studies, 1992-2008.
    J Natl Cancer Inst; 2010 Sep; 102(17):1303. PubMed ID: 20739654
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA approves Novartis's CDK4/6 inhibitor.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(4):229. PubMed ID: 28356596
    [No Abstract]   [Full Text] [Related]  

  • 28. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
    Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA releases tissue-agnostic cancer drug draft guidance.
    Mullard A
    Nat Rev Drug Discov; 2022 Dec; 21(12):868. PubMed ID: 36333480
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-action drug approved for use in advanced breast cancer.
    McBride D
    ONS Connect; 2007 Jun; 22(6):19. PubMed ID: 17598617
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA approves regorafenib (Stivarga) for GIST.
    Oncology (Williston Park); 2013 Mar; 27(3):164. PubMed ID: 23687782
    [No Abstract]   [Full Text] [Related]  

  • 33. Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?
    Kaklamani VG; Gradishar WJ
    J Natl Compr Canc Netw; 2015 Nov; 13(11):1448-52. PubMed ID: 26553770
    [No Abstract]   [Full Text] [Related]  

  • 34. Study bolsters concerns about US FDA accelerated drug approvals.
    Furlow B
    Lancet Oncol; 2024 May; 25(5):543. PubMed ID: 38621403
    [No Abstract]   [Full Text] [Related]  

  • 35. FDA Oncology Center of Excellence Review Processes and Tools.
    Gao JJ; Kluetz PG; Pazdur R
    Clin Pharmacol Ther; 2020 Sep; 108(3):428-429. PubMed ID: 32654129
    [No Abstract]   [Full Text] [Related]  

  • 36. Failure rate: Why many cancer drugs don't receive FDA approval, and what can be done about it.
    Printz C
    Cancer; 2015 May; 121(10):1529-30. PubMed ID: 25946212
    [No Abstract]   [Full Text] [Related]  

  • 37. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials.
    Tibau A; Molto C; Borrell M; Del Paggio JC; Barnadas A; Booth CM; Amir E
    JAMA Oncol; 2018 Nov; 4(11):1610-1611. PubMed ID: 30267037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer.
    Aschenbrenner DS
    Am J Nurs; 2018 Jun; 118(6):26. PubMed ID: 29794918
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019.
    Chen EY; Haslam A; Prasad V
    JAMA Intern Med; 2020 Jun; 180(6):912-914. PubMed ID: 32338703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
    Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.